PMID- 27250027
OWN - NLM
STAT- MEDLINE
DCOM- 20180117
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 26
DP  - 2016 Jun 28
TI  - A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy.
PG  - 40437-40450
LID - 10.18632/oncotarget.9624 [doi]
AB  - Dendritic cells (DCs) are professional antigen-presenting cells with antigen 
      recognition molecules on the surface. Clec9a is selectively expressed on mouse 
      CD8a+ DCs and CD103+ DCs subsets, which are functionally similar to human BDCA3+ 
      DCs. It is reported that Clec9a is responsible for the antigen cross-presentation 
      of these DC subsets. In the present study, by using phage display technique, we 
      discovered a novel peptide WH, which can selectively bind to mouse Flt3L induced 
      Clec9a+ DCs or Clec9a over-expressed HEK-293T cells. Furthermore, by using 
      computer-aided docking model and mutation assay, we observed that Asp248 and 
      Trp250 are two key residues for Clec9a to bind with peptide WH. When coupled with 
      OVA257-264 epitope, peptide WH can significantly enhance the ability of Clec9a+ 
      DCs to activate OVA-specific CD8+ T cells, which elicit strong ability to secret 
      IFN-gamma, express perforin and granzyme B mRNA. In B16-OVA lung metastasis mouse 
      model, WH-OVA257-264 fusion peptide can also enhance the activation of CD8+ T 
      cells and decrease the lung metastasis loci. All these results suggested that 
      peptide WH could be considered as an antigen delivery carrier targeting Clec9a+ 
      DCs for cancer immunotherapy.
FAU - Yan, Zhongyi
AU  - Yan Z
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Wu, Yahong
AU  - Wu Y
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Du, Jiangfeng
AU  - Du J
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Li, Guodong
AU  - Li G
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Wang, Shengdian
AU  - Wang S
AD  - Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
FAU - Cao, Wenpeng
AU  - Cao W
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Zhou, Xiuman
AU  - Zhou X
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Wu, Chunjing
AU  - Wu C
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Zhang, Dan
AU  - Zhang D
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Jing, Xueli
AU  - Jing X
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Li, Yifan
AU  - Li Y
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Wang, Hongfei
AU  - Wang H
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Gao, Yanfeng
AU  - Gao Y
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
AD  - Collaborative Innovation Center of New Drug Research and Safety Evaluation, 
      Zhengzhou, China.
FAU - Qi, Yuanming
AU  - Qi Y
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
AD  - Collaborative Innovation Center of New Drug Research and Safety Evaluation, 
      Zhengzhou, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antigens, CD)
RN  - 0 (CLEC9a protein, human)
RN  - 0 (Epitopes)
RN  - 0 (Integrin alpha Chains)
RN  - 0 (Lectins, C-Type)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Mitogen)
RN  - 0 (alpha E integrins)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 3.4.21.- (Granzymes)
SB  - IM
MH  - Animals
MH  - Antigen Presentation
MH  - Antigens, CD/metabolism
MH  - CD8-Positive T-Lymphocytes/metabolism
MH  - Cell Line, Tumor
MH  - Dendritic Cells/*drug effects
MH  - Epitopes/chemistry
MH  - Granzymes/metabolism
MH  - HEK293 Cells
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Integrin alpha Chains/metabolism
MH  - Interferon-gamma/metabolism
MH  - Lectins, C-Type/*metabolism
MH  - Melanoma, Experimental
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasm Metastasis
MH  - Neoplasms/immunology/*therapy
MH  - Peptides/pharmacology
MH  - Protein Binding
MH  - Receptors, Mitogen/*metabolism
PMC - PMC5130018
OTO - NOTNLM
OT  - Clec9a
OT  - cancer immunotherapy
OT  - dendritic cells
OT  - peptide
COIS- There are no conflicts of interest to disclosure.
EDAT- 2016/10/27 06:00
MHDA- 2018/01/18 06:00
PMCR- 2016/06/28
CRDT- 2016/06/03 06:00
PHST- 2016/02/11 00:00 [received]
PHST- 2016/05/09 00:00 [accepted]
PHST- 2016/10/27 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
PHST- 2016/06/03 06:00 [entrez]
PHST- 2016/06/28 00:00 [pmc-release]
AID - 9624 [pii]
AID - 10.18632/oncotarget.9624 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Jun 28;7(26):40437-40450. doi: 10.18632/oncotarget.9624.